Ten_CD
Largest_NN
Investments_NOMZ
continued_VBD
30_CD
September_NN
2002_CD
Roche_NN
3.4_CD
%_NN
of_PIN
portfolio_NN
,_,
the_DT
Swiss_JJ
pharmaceutical_JJ
group_NN
,_,
has_VPRT [PEAS]
seen_VBN [PRIV]
its_PIT
share_NN
price_NN
outperform_VPRT
the_DT
stock_NN
market_NN
significantly_RB
during_PIN
the_DT
period_NN
._.
Recent_JJ
management_NOMZ
changes_NN
and_CC
a_DT
restructuring_GER
program_NN
should_NEMD
lead_VB
to_TO
rising_VBG
margins_NN
over_IN
the_DT
next_JJ
three_CD
years_NN
._.
Some_QUAN
concerns_NN
remain_VPRT
regarding_VBG
sales_NN
growth_NN
and_PHC
newsflow_NN
on_PIN
drug_NN
development_NOMZ
will_PRMD
be_VB [BEMA]
a_DT
key_JJ
driver_NN
of_PIN
the_DT
share_NN
price_NN
._.
The_DT
companys_NN
existing_VBG [WZPRES]
franchise_NN
in_PIN
the_DT
oncology_NN
market_NN
cancer_NN
treatment_NOMZ
drugs_NN
such_JJ
as_IN
Retaxin_NN
is_VPRT [BEMA]
strong_PRED
,_,
however_CONJ
,_,
and_ANDC
the_DT
shares_NN
are_VPRT [SPAU] [PASS]
attractively_RB
valued_VBN
compared_VBN
to_PIN
peers_NN
._.
UniCredito_NN
Italiano_NN
2.7_CD
%_NN
of_PIN
portfolio_NN
,_,
the_DT
Italian_JJ
retail_JJ
bank_NN
,_,
has_VPRT [PEAS]
delivered_VBN
a_DT
solid_JJ
share_NN
price_NN
performance_NN
relative_JJ
to_PIN
the_DT
market_NN
during_PIN
the_DT
period_NN
._.
The_DT
company_NN
is_VPRT [SPAU] [PASS]
well_RB
managed_VBN
,_,
benefiting_VBG [PRESP]
from_PIN
being_VBG [PASS]
based_VBN
in_PIN
the_DT
more_EMPH
prosperous_JJ
northern_JJ
part_NN
of_PIN
Italy_NN
,_,
and_ANDC
is_VPRT
leading_VBG
consolidation_NOMZ
in_PIN
the_DT
Italian_JJ
banking_GER
sector_NN
._.
The_DT
recent_JJ
acquisition_NOMZ
of_PIN
the_DT
minorities_NOMZ
in_PIN
Rolo_NN
Banca_NN
should_NEMD
lead_VB
to_PIN
further_JJ
efficiency_NN
gains_NN
as_IN
full_JJ
control_NN
of_PIN
operations_NOMZ
is_VPRT [PASS]
established_VBN [PRIV]
._.
Going_VBG [PRESP]
forward_RB
,_,
much_QUAN
will_PRMD
depend_VB
on_PIN
the_DT
performance_NN
of_PIN
the_DT
overall_JJ
economy_NN
,_,
and_ANDC
in_CONJ
particular_NULL
the_DT
quality_NOMZ
of_PIN
their_TPP3
loan_NN
book_NN
._.
Telefonica_NN
2.5_CD
%_NN
of_PIN
portfolio_NN
,_,
the_DT
Spanish_JJ
telecoms_NN
operator_NN
,_,
delivered_VBD
a_DT
disappointing_JJ
share_NN
price_NN
performance_NN
during_PIN
the_DT
period_NN
,_,
as_IN
concerns_NN
about_IN
Latin_JJ
American_JJ
investments_NOMZ
increased_VBD
._.
At_PIN
the_DT
current_JJ
valuation_NOMZ
,_,
we_FPP1
believe_VPRT [PRIV]
that_THVC
these_DEMO
concerns_NN
are_VPRT [PASS]
overdone_VBN
,_,
and_ANDC
are_VPRT [BYPA]
encouraged_VBN
by_PIN
the_DT
companys_NN
withdrawal_NN
from_PIN
onerous_JJ
capital_NN
expenditure_NN
commitments_NOMZ
in_PIN
Germany_NN
._.
In_PIN
Spain_NN
,_,
Telefonica_NN
retains_VPRT
its_PIT
dominant_JJ
market_NN
position_NOMZ
in_PIN
the_DT
provision_NN
of_PIN
both_DT
fixed_VBN
and_CC
mobile_JJ
telecoms_NN
services_NN
._.
Cash_NN
generation_NOMZ
is_VPRT [BEMA]
strong_PRED
and_CC
the_DT
balance_NN
sheet_NN
looks_VPRT
robust_JJ
._.
However_CONJ
,_,
uncertainty_NN
over_IN
Latin_NN
America_NN
may_POMD
prevent_VB
the_DT
share_NN
price_NN
from_PIN
rallying_VBG
in_PIN
the_DT
short-term_JJ
._.
E._NN
On_PIN
2.4_CD
%_NN
of_PIN
portfolio_NN
,_,
the_DT
German_JJ
utility_NOMZ
company_NN
,_,
continued_VBD
its_PIT
strategy_NN
of_PIN
refocusing_VBG
on_PIN
the_DT
core_NN
electricity_NOMZ
and_PHC
gas_NN
business_NOMZ
._.
The_DT
share_NN
price_NN
performance_NN
over_IN
the_DT
past_JJ
six_CD
months_NN
has_VPRT [PEAS]
reflected_VBN [PRIV] [THATD]
the_DT
markets_NN
growing_VBG [WZPRES]
confidence_NN
in_PIN
this_DEMO
strategy_NN
,_,
as_RB
well_RB
as_IN
the_DT
security_NOMZ
of_PIN
the_DT
companys_NN
earnings_GER
,_,
despite_PIN
weak_JJ
economic_JJ
growth_NN
._.
With_PIN
German_JJ
electricity_NOMZ
prices_NN
rising_VBG [WZPRES]
,_,
the_DT
core_NN
business_NOMZ
is_VPRT
performing_VBG
better_JJ
than_PIN
expected_VBN [PRIV]
._.
Reinvestment_NOMZ
risks_NN
regarding_VBG [WZPRES]
future_JJ
acquisitions_NOMZ
remains_VPRT
a_DT
key_JJ
concern_NN
for_PIN
investors_NN
,_,
but_CC
are_VPRT [BEMA]
more_EMPH
than_PIN
reflected_VBN [PRIV]
in_PIN
the_DT
current_JJ
share_NN
price_NN
._.
Aventis_NN
2.3_CD
%_NN
of_PIN
portfolio_NN
,_,
the_DT
French_JJ
pharmaceutical_JJ
company_NN
,_,
has_VPRT [PEAS]
seen_VBN [PRIV]
its_PIT
share_NN
price_NN
perform_VB
well_RB
relative_JJ
to_PIN
the_DT
market_NN
._.
The_DT
sale_NN
of_PIN
the_DT
agro-chemical_JJ
business_NOMZ
to_PIN
Bayer_NN
should_NEMD
allow_VB [SUAV]
the_DT
management_NOMZ
to_TO
focus_VB
on_PIN
growing_VBG
Aventis_NN
core_NN
business_NOMZ
._.
The_DT
restructuring_GER
implemented_VBD
over_IN
the_DT
past_JJ
two_CD
years_NN
is_VPRT
bearing_VBG
fruits_NN
on_PIN
both_DT
revenues_NN
and_PHC
earnings_GER
._.
The_DT
shares_NN
look_VPRT
attractively_RB
valued_VBN
and_CC
concerns_NN
surrounding_VBG [WZPRES]
the_DT
competitive_JJ
threat_NN
to_PIN
Allegra_NN
,_,
an_DT
anti-histamine_JJ
,_,
are_VPRT [BEMA]
most_EMPH
likely_PRED
overdone_VBN
._.
